Seminar at SciLifeLabs by Professor Neil Forbes - pioneer of genetically modified bacteria for treatment of solid tumors
Today there are >20 drug candidates that are genetically modified bacteria have been or are evaluated in clinical trials in a wide range of medical indications.
"Promoting healing of skin and mucosa by immunomodulation using CXCL12 producing lactic acid bacteria: From bench to bedside" by Industrial PhD student Emelie Öhnstedt.
Interested in learning more about Ilyas's ILP-technology, local-acting immunotherapies or any of the trials SITU-SAFE, SITU-SURGERY, SITU-HEAL or SITU-GUT or our recent work in AMR and meet our CEO Evelina Vågesjö, please reach out.
Nailing of a Thesis - "Live Biotherapeutics - Importance of formulation and lyophilization parameters and an example of a clinical application"
The thesis will be defended in a hearing open to the public at the Swedish University of Agricultural Sciences on Tuesday 5th September (09:00-12:00) in Undervisningshuset Sal L, SLU, Uppsala.
Dr Andreas Fasth will present the planned SITU-SURGERY trial at the US Military partnering conference MHSRS in Kissimmee, FL on August 16
For the third consecutive year Ilya Pharma is invited to share updates regarding its ILP100-Topical program to the US Military largest medical conference, Military Health Systems Research Symposium (MHSRS).
Dr Evelina Vagesjö will give clinical update at The European Chemokine and Cell Migration Conference (ECMC) 2023 August 21st, Leuven, BE